Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "Vitiligo Market Report, Forecast by Diseases Type, Treatment Type, End User, Countries and Company Analysis, 2024-2032" report has been added to ResearchAndMarkets.com's offering.
The global vitiligo market is worth around US$ 641 billion in 2023 and it is expected to reach approximately US$ 1.04 trillion by 2032, with a CAGR of about 5.55% from 2024-2032. The measures that are benefiting this market include enhanced knowledge of people about vitiligo, as well as the innovations that are availed for treatment. 
Vitiligo is a chronic ailment that is classified under the autoimmune disorders which results to depigmentation and manifest in white colors parts of the body. This condition results from either the death of melanocytes, or stop work, and therefore no skin color is produced. The cause of vitiligo though not well defined, the fatty diet is believed to be inherited though some factors from the environment.
Vitiligo management strategies encompass measures that seek to reform the depigmented skin and strop further progression. These are Topical corticosteroids and immunomodulators, Phototherapy (UVB light or PUVA), Oral medications for corticosteroids or JAK inhibitors, depigmentation in severe cases and Skin grafting or cellular grafting in certain conditions.
Furthermore, camouflage makeup and self-tanning products are effective ways of covering areas with certain skin conditions. Counseling could also help for, as vitiligo is becoming a source of stress or depression among affected people. Currently, there is no known cure for vitiligo, though the above treatments are effective in managing patients' condition and enhancing their appearance. The need for further research means that new therapeutic interventions' possibilities are still pursued today.
Growth Drivers of the Global Vitiligo Market
Increasing prevalence and awareness:
Currently, vitiligo is becoming more widespread and is primarily diagnosed in between 1 and 2 percent of the total global population. This rise is attributed to enhanced detecting methods and specially increased patient awareness and that of healthcare practitioners. When more people identify the signs and symptoms of the diseases, and visit the doctors, there is increase in the market for the medication.
Having personalities such as musician Beyonce or footballer Marc Batchelor come out in the open to publicly share their experiences with vitiligo have gone a long way in eradicating or at least reducing the stigmatization of the persons afflicted with vitiligo. It also increases an awareness of the conditions among people, thereby motivating them to come for treatment and the progression of the market.
On the same note, the roles of patients' organizations and informative campaigns play a vital role in informing the community, and the general public more often on vitiligo and its effects on the life of an affected patient together with the existing treatment modalities. These increasing awareness levels are expected to drive the market in the future years.
Advancements in treatment options:
The present activity of increasing research in the pharmacological sector to develop new products in the management of vitiligo is extending the market widely. Some recent advancements are Janus kinase inhibitors which have emerged to be effective in the clinical trials. These new drugs hold the potential for more effective and indeed, targeted thanks to this new generation, therapy of this and other diseases. Moreover, advancement in the source of light and technology as well as advancement in treating techniques including the technique of giving narrowband UVB and the application of excimer laser therapy in treatment have been enhancing.
Combination treatments in which two or more techniques are used are becoming more popular as they provide better results. Other areas of growth involve the usage of genetic and environmental factors in developing targeted medical solutions for the individual patient including personalized medicine approaches. These new generation treatments are projected to fuel the growth and get more acceptance from approval bodies hence propelling the growth of vitiligo treatment market and attract investors.
Growing aesthetic concerns and quality of life considerations:
In today's world where people are sensitive about esteeming concerns, looks appear to take on a social and or professional value. Vitiligo, an easily noticeable skin disorder, plays a large role in the patient's low self-esteem and a diminished quality of life. This coupled with the increasing concern from people, treatment therapies that are non-surgical are in high demand as people seek ear treatments not only for health issues but also for cosmetic and morale boosting purposes. This aspect of the treatment with vitiligo is also beginning to shape the market significantly with patients demanding solutions to regain the lost skin color.
This trend is particularly strong across the generations with increased influence among the young and in areas where the culture placed significant emphasis on the appearance of an individual. The market is using every possible product, ranging from medical, to make-up creams and dyes that address these issues. Hence the focus on quality of life and appearance will contribute to the continuous growth of vitiligo treatment market.
United States Vitiligo Market
The United States vitiligo market is today deemed as one of the most significant and promising submarkets in the global dermatology industry. Currently, it is predicted that between 2 to 5 million Americans suffer from vitiligo hence the market is ripe for expansion and development. The U. S. market enjoys a strong health care infrastructure, high health care awareness, and research and development financial outlay.
Some of the leading market players are currently working on creating new drugs, moreover, most of the initiatives are aimed at the creation of biologics and targeted therapies. For instance, the latest approval of ruxolitinib cream for vitiligo therapy has given a boost into the market and thus opening up new innovations. Besides, there has been growth in the use of 'dual-hit therapies' as well as 'treat the patient' regimen.
The U. S. vitiligo market therefore has also strong patient associations that are very useful in raising public awareness and campaigning for improved therapy. These factors entailing favourable reimbursement policies along with increased focus on cosmetic and aesthetic issues are expected to help the vitiligo market in the U. S. to grow in the future years.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value (USD) in 2023 | $641 Million |
| Forecasted Market Value (USD) by 2032 | $1041 Million |
| Compound Annual Growth Rate | 5.5% |
| Regions Covered | Global |
Competitive Landscape
- Incyte Corporation
- Bristol-Myers Squibb
- Clinuvel Pharmaceuticals Ltd
- Astellas pharma inc
- Baxter International Inc.
- Pfizer
- Dr. Reddy's Laboratories Ltd
Global Vitiligo Company Analysis
- Ritlecitinib (PF-06651600): An oral JAK3/TEC inhibitor developed by Pfizer, currently in Phase 3 trials.
- ATI-502: A topical JAK1/JAK3 inhibitor by Aclaris Therapeutics, in Phase 2 development.
- Cerdulatinib: A topical dual JAK/SYK inhibitor by Dermavant Sciences, undergoing Phase 2 trials.
- Roflumilast cream: A PDE4 inhibitor by Arcutis Biotherapeutics, in Phase 2 studies for vitiligo.
- IL-15 agonist: A novel approach by Immunocore, targeting melanocyte stimulation in preclinical stages.
- ARQ-252: A topical JAK1 selective inhibitor by Arcutis Biotherapeutics in early clinical development.
- VTP-38543: An LXR? agonist by Vitae Pharmaceuticals aimed at promoting melanocyte differentiation.
- Afamelanotide: A synthetic hormone by Clinuvel Pharmaceuticals in late-stage trials for vitiligo.
- KB301: A gene therapy approach by Krystal Biotech designed to deliver functional TYR genes to melanocytes.
- VM206: A novel small molecule by Vilacto Bio targeting melanocyte regeneration in preclinical development.
Vitiligo Pipe Line Drugs
- AMG-714: Amgen
- ARN-4079
- ATI-502
- AX-1602
- BOS-475
- CCP-070
- Cerdulatinib (RVT-502)
- HuABC-2
- Abatacept
- Topical Ruxolitinib
- VLRX-001
By Diseases Type - Market is divided into 4 viewpoints
- Segmental
- Non-Segmental
Treatment Type - Market is divided into 4 viewpoints
- Topical Treatments
- Light Therapy
- Surgical Procedures
- Others
End User - Market is divided into 3 viewpoints
- Hospitals
- Ambulatory Clinics
- Others
Country - 18 Country Vitiligo Patient Numbers & Market
- United States
- Canada
- Mexico
- Germany
- United Kingdom
- France
- Italy
- Spain
- Japan
- China
- Australia
- India
- Brazil
- Saudi Arabia
- Argentina
- United Arab Emirates
- South Africa
- Rest of World
For more information about this report visit https://www.researchandmarkets.com/r/mqoa4j
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
